Although some studies have shown very promising results in targeting IL-6–IL-6R axis with Tocilizumab (Esfahani et al. 2020; Kampan et al. 2018; Stroud et al. 2019), concern remains, if manipulation of IL-6 may also support tumor growth as it has been discussed in the past (Kumari et al. 2016). This evidence concerns the gene IL6 and neoplasm.